Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias

Cancers

Volumn 6, Issue 2, 2014, Pages 796-812

  Bouchet, Sandrine ^a   Bauvois, Brigitte ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Cancer; Cell surface binding; Gelatinase; Hematologic malignancy; Signalling

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; GELATINASE B; HERMES ANTIGEN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; LEUKEMIA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR GROWTH;

EID: 84898786246     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6020796     Document Type: Review

References (103)

1. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141, 52-67.
2. Klein, T.; Bischoff, R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011, 41, 271-290.
3. Triebel, S.; Blaser, J.; Reinke, H.; Tschesche, H. A 25 kda alpha 2-microglobulin-related protein is a component of the 125 kda form of human gelatinase. FEBS Lett. 1992, 314, 386-388.
4. Kjeldsen, L.; Johnsen, A.H.; Sengelov, H.; Borregaard, N. Isolation and primary structure of ngal, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993, 268, 10425-10432.
5. Rydlova, M.; Holubec, L., Jr.; Ludvikova, M., Jr.; Kalfert, D.; Franekova, J.; Povysil, C.; Ludvikova, M. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008, 28, 1389-1397.
6. Roy, R.; Yang, J.; Moses, M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27, 5287-5297.
7. Chakraborty, S.; Kaur, S.; Guha, S.; Batra, S.K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 2012, 1826, 129-169.
8. Makris, K.; Kafkas, N. Neutrophil gelatinase-associated lipocalin in acute kidney injury. Adv. Clin. Chem. 2012, 58, 141-191.
9. Yang, J.; Moses, M.A. Lipocalin 2: A multifaceted modulator of human cancer. Cell Cycle 2009, 8, 2347-2352.
10. Bolignano, D.; Donato, V.; Lacquaniti, A.; Fazio, M.R.; Bono, C.; Coppolino, G.; Buemi, M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. Cancer Lett. 2010, 288, 10-16.
11. Klein, G.; Vellenga, E.; Fraaije, M.W.; Kamps, W.A.; de Bont, E.S. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g., acute leukemia. Crit. Rev. Oncol. Hematol. 2004, 50, 87-100.
12. Yu, X.F.; Han, Z.C. Matrix metalloproteinases in bone marrow: Roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol. Histopathol. 2006, 21, 519-531.
13. Poyer, F.; Coquerel, B.; Pegahi, R.; Cazin, L.; Norris, V.; Vannier, J.P.; Lamacz, M. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk. Res. 2009, 33, 407-417.
14. Schneider, P.; Costa, O.; Legrand, E.; Bigot, D.; Lecleire, S.; Grassi, V.; Vannier, J.P.; Vasse, M. In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia. Leuk. Res. 2010, 34, 24-31.
15. Vandooren, J.; van den Steen, P.E.; Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit. Rev. Biochem. Mol. Biol. 2013, 48, 222-272.
16. Malla, N.; Sjoli, S.; Winberg, J.O.; Hadler-Olsen, E.; Uhlin-Hansen, L. Biological and pathobiological functions of gelatinase dimers and complexes. Connect. Tissue Res. 2008, 49, 180-184.
17. Kjeldsen, L.; Bjerrum, O.W.; Hovgaard, D.; Johnsen, A.H.; Sehested, M.; Borregaard, N. Human neutrophil gelatinase: A marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay. Eur. J. Haematol. 1992, 49, 180-191.
18. Bauvois, B.; Dumont, J.; Mathiot, C.; Kolb, J.P. Production of matrix metalloproteinase-9 in early stage B-CLL: Suppression by interferons. Leukemia 2002, 16, 791-798.
19. Provatopoulou, X.; Gounaris, A.; Kalogera, E.; Zagouri, F.; Flessas, I.; Goussetis, E.; Nonni, A.; Papassotiriou, I.; Zografos, G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9, 390.
20. Miharada, K.; Hiroyama, T.; Sudo, K.; Danjo, I.; Nagasawa, T.; Nakamura, Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J. Cell Physiol. 2008, 215, 526-537.
21. Janowska-Wieczorek, A.; Marquez, L.A.; Matsuzaki, A.; Hashmi, H.R.; Larratt, L.M.; Boshkov, L.M.; Turner, A.R.; Zhang, M.C.; Edwards, D.R.; Kossakowska, A.E. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: Comparison with normal bone marrow cells. Br. J. Haematol. 1999, 105, 402-411.
22. Borregaard, N.; Cowland, J.B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997, 89, 3503-3521.
23. Marquez-Curtis, L.A.; Dobrowsky, A.; Montano, J.; Turner, A.R.; Ratajczak, J.; Ratajczak, M.Z.; Janowska-Wieczorek, A. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br. J. Haematol. 2001, 115, 595-604.
24. Trocme, C.; Gaudin, P.; Berthier, S.; Barro, C.; Zaoui, P.; Morel, F. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J. Biol. Chem. 1998, 273, 20677-20684.
25. Weeks, B.S.; Schnaper, H.W.; Handy, M.; Holloway, E.; Kleinman, H.K. Human T lymphocytes synthesize the 92 kDa type IV collagenase (gelatinase B). J. Cell Physiol. 1993, 157, 644-649.
26. Montgomery, A.M.; Sabzevari, H.; Reisfeld, R.A. Production and regulation of gelatinase B by human t-cells. Biochim. Biophys. Acta 1993, 1176, 265-268.
27. Fuchs, O. Transcription factor NF-κb inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr. Mol. Pharmacol. 2010, 3, 98-122.
28. Pleyer, L.; Egle, A.; Hartmann, T.N.; Greil, R. Molecular and cellular mechanisms of CLL: Novel therapeutic approaches. Nat. Rev. Clin. Oncol. 2009, 6, 405-418.
29. Kamiguti, A.S.; Lee, E.S.; Till, K.J.; Harris, R.J.; Glenn, M.A.; Lin, K.; Chen, H.J.; Zuzel, M.; Cawley, J.C. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br. J. Haematol. 2004, 125, 128-140.
30. Molica, S.; Vitelli, G.; Levato, D.; Giannarelli, D.; Vacca, A.; Cuneo, A.; Cavazzini, F.; Squillace, R.; Mirabelli, R.; Digiesi, G. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur. J. Haematol. 2003, 70, 373-378.
31. Aref, S.; Salama, O.; Shamaa, S.; El-Refaie, M.; Mourkos, H. Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology 2007, 12, 319-324.
32. Van Vlierberghe, P.; Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 2012, 122, 3398-3406.
33. Kuittinen, O.; Savolainen, E.R.; Koistinen, P.; Mottonen, M.; Turpeenniemi-Hujanen, T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (all). Leuk. Res. 2001, 25, 125-131.
34. Hayashibara, T.; Yamada, Y.; Onimaru, Y.; Tsutsumi, C.; Nakayama, S.; Mori, N.; Miyanishi, T.; Kamihira, S.; Tomonaga, M.; Maita, T. Matrix metalloproteinase-9 and vascular endothelial growth factor: A possible link in adult T-cell leukaemia cell invasion. Br. J. Haematol. 2002, 116, 94-102.
35. Lin, L.I.; Lin, D.T.; Chang, C.J.; Lee, C.Y.; Tang, J.L.; Tien, H.F. Marrow matrix metalloproteinases (mmps) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol. 2002, 117, 835-841.
36. Kim, J.G.; Sohn, S.K.; Kim, D.H.; Baek, J.H.; Lee, N.Y.; Suh, J.S.; Chae, S.C.; Lee, K.S.; Lee, K.B. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk. Lymphoma 2005, 46, 885-891.
37. Krawczuk-Rybak, M.; Kuzmicz, M.; Mroczko, B.; Szmitkowski, M. Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia. Pol. Merkur. Lekarski 2010, 29, 14-18.
38. Piedfer, M.; Dauzonne, D.; Tang, R.; N'Guyen, J.; Billard, C.; Bauvois, B. Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 2011, 25, 2831-2842.
39. Laouar, A.; Villiers, C.; Sanceau, J.; Maison, C.; Colomb, M.; Wietzerbin, J.; Bauvois, B. Inactivation of interleukin-6 in vitro by monoblastic U937 cell plasma membranes involves both protease and peptidyl-transferase activities. Eur. J. Biochem. 1993, 215, 825-831.
40. Burke, B.A.; Carroll, M. BCR-ABL: A multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 2010, 24, 1105-1112.
41. Bixby, D.; Talpaz, M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011, 25, 7-22.
42. Bisen, A.; Claxton, D.F. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv. Exp. Med. Biol. 2013, 779, 179-196.
43. Ries, C.; Loher, F.; Zang, C.; Ismair, M.G.; Petrides, P.E. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin. Cancer Res. 1999, 5, 1115-1124.
44. Janowska-Wieczorek, A.; Majka, M.; Marquez-Curtis, L.; Wertheim, J.A.; Turner, A.R.; Ratajczak, M.Z. BCR-ABL-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in matrigel implants. Leukemia 2002, 16, 1160-1166.
45. Kaneta, Y.; Kagami, Y.; Tsunoda, T.; Ohno, R.; Nakamura, Y.; Katagiri, T. Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int. J. Oncol. 2003, 23, 681-691.
46. Leng, X.; Lin, H.; Ding, T.; Wang, Y.; Wu, Y.; Klumpp, S.; Sun, T.; Zhou, Y.; Monaco, P.; Belmont, J. et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 2008, 27, 6110-6119.
47. Villalva, C.; Sorel, N.; Bonnet, M.L.; Guilhot, J.; Mayeur-Rousse, C.; Guilhot, F.; Chomel, J.C.; Turhan, A.G. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk. Lymphoma 2008, 49, 984-988.
48. Alonci, A.; Allegra, A.; Russo, S.; Penna, G.; Bellomo, G.; D'Angelo, A.; Campo, S.; Cannavo, A.; Centorrino, R.; Musolino, C. Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol. 2012, 127, 1-6.
49. Meenaghan, T.; Dowling, M.; Kelly, M. Acute leukaemia: Making sense of a complex blood cancer. Br. J. Nurs. 2012, 21, 78-83.
50. Swords, R.; Freeman, C.; Giles, F. Targeting the fms-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012, 26, 2176-2185.
51. Billard, C.; Merhi, F.; Bauvois, B. Mechanistic insights into the antileukemic activity of hyperforin. Curr. Cancer Drug Targets 2013, 13, 1-10.
52. Aref, S.; El-Sherbiny, M.; Mabed, M.; Menessy, A.; El-Refaei, M. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: A possible relation to disease invasion. Hematology 2003, 8, 385-391.
53. Yang, W.C.; Lin, P.M.; Yang, M.Y.; Liu, Y.C.; Chang, C.S.; Chou, W.C.; Hsu, J.F.; Huang, C.T.; Cho, S.F.; Yu, W.H. et al. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Leuk. Lymphoma 2013, 54, 1614-1625.
54. St-Pierre, Y.; Couillard, J.; van Themsche, C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin. Ther. Targets 2004, 8, 473-489.
55. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883-899.
56. Allavena, P.; Sica, A.; Solinas, G.; Porta, C; Mantovani, A. The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66, 1-9.
57. Aggarwal, B.B.; Shishodia, S.; Sandur, S.K.; Pandey, M.K.; Sethi, G. Inflammation and cancer: How hot is the link? Biochem. Pharmacol. 2006, 72, 1605-1621.
58. Sheu, B.C.; Hsu, S.M.; Ho, H.N.; Lien, H.C.; Huang, S.C.; Lin, R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001, 61, 237-242.
59. Agrawal, S.; Anderson, P.; Durbeej, M.; van Rooijen, N.; Ivars, F.; Opdenakker, G; Sorokin, L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 2006, 203, 1007-1019.
60. Fridman, R.; Toth, M.; Chvyrkova, I.; Meroueh, S.O.; Mobashery, S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 2003, 22, 153-166.
61. Van den Steen, P.E.; van Aelst, I.; Hvidberg, V.; Piccard, H.; Fiten, P.; Jacobsen, C; Moestrup, S.K.; Fry, S.; Royle, L.; Wormald, M.R. et al. The hemopexin and o-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem. 2006, 281, 18626-18637.
62. Bauvois, B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 2012, 1825, 29-36.
63. Buggins, A.G; Levi, A.; Gohil, S.; Fishlock, K.; Patten, P.E.; Calle, Y.; Yallop, D.; Devereux, S. Evidence for a macromolecular complex in poor prognosis cll that contains CD38, CD49d, CD44 and MMP-9. Br. J. Haematol. 2011, 154, 216-222.
64. Hu, Y.; Ivashkiv, L.B. Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of ifn-alpha dendritic cells. J. Immunol. 2006, 176, 6022-6033.
65. Stefanidakis, M.; Ruohtula, T.; Borregaard, N.; Gahmberg, C.G.; Koivunen, E. Intracellular and cell surface localization of a complex between amp2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. J. Immunol. 2004, 172, 7060-7068.
66. Redondo-Munoz, J.; Ugarte-Berzal, E.; Terol, M.J.; van den Steen, P.E.; Hernandez del Cerro, M.; Roderfeld, M.; Roeb, E.; Opdenakker, G.; Garcia-Marco, J.A.; Garcia-Pardo, A. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 2010, 17, 160-172.
67. Miller, R.E.; Fayen, J.D.; Chakraborty, S.; Weber, M.C.; Tykocinski, M.L. A receptor for the lipocalin placental protein 14 on human monocytes. FEBS Lett. 1998, 436, 455-460.
68. Fang, W.K.; Xu, L.Y.; Lu, X.F.; Liao, L.D.; Cai, W.J.; Shen, Z.Y.; Li, E.M. A novel alternative spliced variant of neutrophil gelatinase-associated lipocalin receptor in oesophageal carcinoma cells. Biochem. J. 2007, 403, 297-303.
69. Hvidberg, V.; Jacobsen, C; Strong, R.K.; Cowland, J.B.; Moestrup, S.K.; Borregaard, N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005, 579, 773-777.
70. Devarajan, P. Neutrophil gelatinase-associated lipocalin: New paths for an old shuttle. Cancer Ther. 2007, 5, 463-470.
71. Tong, Z.; Wu, X.; Ovcharenko, D.; Zhu, J.; Chen, C.S.; Kehrer, J.P. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 2005, 391, 441-448.
72. Hu, L.; Hittelman, W.; Lu, T.; Ji, P.; Arlinghaus, R.; Shmulevich, I.; Hamilton, S.R.; Zhang, W. Ngal decreases e-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab. Investig. 2009, 89, 531-548.
73. Nuntagowat, C.; Leelawat, K.; Tohtong, R. Ngal knockdown by sirna in human cholangiocarcinoma cells suppressed invasion by reducing ngal/mmp-9 complex formation. Clin. Exp. Metastasis 2010, 27, 295-305.
74. Fernandez, C.A.; Yan, L.; Louis, G.; Yang, J.; Kutok, J.L.; Moses, M.A. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 2005, 11, 5390-5395.
75. Lee, E.K.; Kim, H.J.; Lee, K.J.; Lee, H.J.; Lee, J.S.; Kim, D.G.; Hong, S.W.; Yoon, Y.; Kim, J.S. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/AKT signaling. Int. J. Oncol. 2011, 38, 325-333.
76. Tong, Z.; Kunnumakkara, A.B.; Wang, H.; Matsuo, Y.; Diagaradjane, P.; Harikumar, K.B.; Ramachandran, V.; Sung, B.; Chakraborty, A.; Bresalier, R.S. et al. Neutrophil gelatinase-associated lipocalin: A novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008, 68, 6100-6108.
77. Bahmani, P.; Halabian, R.; Rouhbakhsh, M.; Roushandeh, A.M.; Masroori, N.; Ebrahimi, M.; Samadikuchaksaraei, A.; Shokrgozar, M.A.; Roudkenar, M.H. Neutrophil gelatinase-associated lipocalin induces the expression of heme oxygenase-1 and superoxide dismutase 1, 2. Cell Stress Chaperones 2010, 15, 395-403.
78. Chappell, W.H.; Abrams, S.L.; Montalto, G.; Cervello, M.; Martelli, A.M.; Candido, S.; Libra, M.; Polesel, J.; Talamini, R.; Arlinghaus, R. et al. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012, 3, 1236-1245.
79. Wang, L.H.; Chang, G.Q.; Zhang, H.J.; Wang, J.; Lin, Y.N.; Jin, W.N.; Li, H.W.; Gao, W.; Wang, R.J.; Li, Q.H. et al. Neutrophil gelatinase-associated lipocalin regulates intracellular accumulation of Rh123 in cancer cells. Genes Cells 2012, 17, 205-217.
80. Krysan, K.; Cui, X.; Gardner, B.K.; Reckamp, K.L.; Wang, X.; Hong, L.; Walser, T.C.; Rodriguez, N.L.; Pagano, P.C.; Garon, E.B. et al. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am. J. Transl. Res. 2013, 5, 481-496.
81. Kubben, F.J.; Sier, C.F.; Hawinkels, L.J.; Tschesche, H.; van Duijn, W.; Zuidwijk, K.; van der Reijden, J.J.; Hanemaaijer, R.; Griffioen, G.; Lamers, C.B. et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur. J. Cancer 2007, 43, 1869-1876.
82. Hiromoto, T.; Noguchi, K.; Yamamura, M.; Zushi, Y.; Segawa, E.; Takaoka, K.; Moridera, K.; Kishimoto, H.; Urade, M. Up-regulation of neutrophil gelatinase-associated lipocalin in oral squamous cell carcinoma: Relation to cell differentiation. Oncol. Rep. 2011, 26, 1415-1421.
83. Volpe, V.; Raia, Z.; Sanguigno, L.; Somma, D.; Mastrovito, P.; Moscato, F.; Mellone, S.; Leonardi, A.; Pacifico, F. NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2013, 98, 228-235.
84. Tschesche, H.; Zolzer, V.; Triebel, S.; Bartsch, S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur. J. Biochem. 2001, 268, 1918-1928.
85. Yan, L.; Borregaard, N.; Kjeldsen, L.; Moses, M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001, 276, 37258-37265.
86. Lee, H.J.; Lee, E.K.; Lee, K.J.; Hong, S.W.; Yoon, Y.; Kim, J.S. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. J. Int. Cancer 2006, 118, 2490-2497.
87. Bannikov, G.A.; Karelina, T.V.; Collier, I.E.; Marmer, B.L.; Goldberg, G.I. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J. Biol. Chem. 2002, 277, 16022-16027.
88. Geurts, N.; Martens, E.; van Aelst, I.; Proost, P.; Opdenakker, G.; van den Steen, P.E. Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 2008, 47, 2689-2699.
89. Barille, S.; Akhoundi, C; Collette, M.; Mellerin, M.P.; Rapp, M.J.; Harousseau, J.L.; Bataille, R.; Amiot, M. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997, 90, 1649-1655.
90. Kelly, T.; Borset, M.; Abe, E.; Gaddy-Kurten, D.; Sanderson, R.D. Matrix metalloproteinases in multiple myeloma. Leuk. Lymphoma 2000, 37, 273-281.
91. Sakata, K.; Satoh, M.; Someya, M.; Asanuma, H.; Nagakura, H.; Oouchi, A.; Nakata, K.; Kogawa, K.; Koito, K.; Hareyama, M. et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004, 100, 356-365.
92. Vande Broek, I.; Asosingh, K.; Allegaert, V.; Leleu, X.; Facon, T.; Vanderkerken, K.; van Camp, B.; van Riet, I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: Evidence for a role of hepatocyte growth factor. Leukemia 2004, 18, 976-982.
93. Kossakowska, A.E.; Urbanski, S.J.; Janowska-Wieczorek, A. Matrix metalloproteinases and their tissue inhibitors-expression, role and regulation in human malignant non-Hodgkin's lymphomas. Leuk. Lymphoma 2000, 39, 485-493.
94. Li, J.; Ji, C; Zheng, H.; Fei, X.; Zheng, M.; Dai, J.; Gu, S.; Xie, Y.; Mao, Y. Molecular cloning and characterization of a novel human gene containing 4 ankyrin repeat domains. Cell Mol. Biol. Lett. 2005, 10, 185-193.
95. Borrell-Pages, M.; Romero, J.C.; Juan-Babot, O.; Badimon, L. Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages. Eur. Heart J. 2011, 32, 2841-2850.
96. Stefanidakis, M.; Koivunen, E. Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression. Blood 2006, 108, 1441-1450.
97. Hertweck, M.K.; Erdfelder, F.; Kreuzer, K.A. CD44 in hematological neoplasias. Ann. hematol. 2011, 90, 493-508.
98. Lopez-Otin, C; Matrisian, L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7, 800-808.
99. Murphy, G.; Nagase, H. Progress in matrix metalloproteinase research. Mol. Asp. Med. 2008, 29, 290-308.
100. Bjorklund, M.; Heikkila, P.; Koivunen, E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J. Biol. Chem. 2004, 279, 29589-29597.
101. Mantuano, E.; Inoue, G.; Li, X.; Takahashi, K.; Gaultier, A.; Gonias, S.L.; Campana, W.M. The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J. Neurosci. 2008, 28, 11571-11582.
102. Dufour, A.; Zucker, S.; Sampson, N.S.; Kuscu, C; Cao, J. Role of matrix metalloproteinase-9 dimers in cell migration: Design of inhibitory peptides. J. Biol. Chem. 2010, 285, 35944-35956.
103. Ugarte-Berzal, E.; Bailon, E.; Amigo-Jimenez, I.; Vituri, C.L.; del Cerro, M.H.; Terol, M.J.; Albar, J.P.; Rivas, G; Garcia-Marco, J.A.; Garcia-Pardo, A. A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds a4p1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells. J. Biol. Chem. 2012, 287, 27601-27613.